XTENT, which is developing a customizable drug eluting stent to treat coronary artery disease, priced its 4.7 million share IPO at $16, the low end of its proposed $16 to $18 range, on Wednesday night. Piper Jaffray was the lead underwriter on the deal. The stock is expected to begin trading on the NASDAQ under the ticker XTNT on Thursday.
